(Reuters) – COVID-19 patients with pneumonia improved faster when administered with its experimental therapy than those on placebo, Vanda Pharmaceuticals Inc said on Tuesday, citing an interim analysis of data from a late-stage study.
Vanda said the data was from 60 patients enrolled in the trial, which aims to enroll 300 patients eventually.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)
